Biotech IPOs heated up to start 2024. Will the surge last?
Bio Pharma Dive
MARCH 5, 2024
Following the sector’s best IPO start in three years, BioPharma Dive spoke with industry insiders about what they expect to see in the months ahead.
Tue.Mar 05, 2024
200 
UK NHS introduces new endometrial cancer immunotherapy
Pharmaceutical Technology
MARCH 5, 2024
The UK NHS has introduced the new checkpoint inhibitor immunotherapy dostarlimab (Jemperli) for women with advanced endometrial cancer.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alnylam, Roche blood pressure drug scores in second mid-stage trial
Bio Pharma Dive
MARCH 5, 2024
The study results further validate Roche’s recent decision to acquire rights to the drug, which is being developed for people with a stubborn form of hypertension.
Cheap Daily Supplement Seems to Boost Brain Function in Older Adults
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 5, 2024
What’s good for your aging gut may also be good for your aging brain. The first twin study of its kind suggests that taking daily protein and prebiotic supplements can improve scores on memory tests in people over the age of 60.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bayer isn’t splitting up, for now
Bio Pharma Dive
MARCH 5, 2024
Company shares fell after executives disclosed plans to, at least temporarily, keep its three main divisions under one roof.
SEC recommends approval for Astrazeneca’s anti-hyperkalaemia drug Lokelma in India
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 5, 2024
The Subject Expert Committee (SEC) which advises the national drug regulator on drug approvals and clinical trials has recommended grant of permission to drug major Astrazeneca for import and marketing of two strengths of anti-hyperkalaemia therapy drug Lokelma (sodium zirconium cyclosilicate for oral suspension).
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Telix to acquire Canadian radioisotope tech company ARTMS
Pharmaceutical Technology
MARCH 5, 2024
Telix Pharmaceuticals has signed an agreement for the acquisition of ARTMS, a Canadian radioisotope production technology company.
Apogee data hint at potential for long-lasting eczema drug
Bio Pharma Dive
MARCH 5, 2024
The biotech, which raised $300 million in an IPO last year, disclosed early results suggesting its therapy could be dosed less frequently than medicines from Eli Lilly and Regeneron.
Unveiling the Power of Holistic Wellness: A Path to Better Sleep
Pharma Mirror
MARCH 5, 2024
Presented by BetterHelp. Wellness is an important focus for most people. The concept of holistic wellness involves taking care of the mind and body. It can include conventional modern medicine, psychotherapy, and various activities to bring calm and balance to one’s life. The term ‘’mind, body, and spirit’’ is sometimes used to illustrate this holistic approach to health.
UK Spring Budget allocates funds to life sciences manufacturing
Pharmaceutical Technology
MARCH 5, 2024
The UK Government announced plans to bolster the UK life science manufacturing industry through increased investment.
Novo Nordisk's success with Ozempic in diabetes and kidney disease patients isn't enough for investors
Fierce Pharma
MARCH 5, 2024
A trial of Novo Nordisk's Ozempic on diabetes and kidney disease patients found that it reduced the risk of disease progression and death by 24%.
F. Hoffmann-La Roche in artificial intelligence: theme innovation strategy
Pharmaceutical Technology
MARCH 5, 2024
How many patents did F. Hoffmann-La Roche submit related to artificial intelligence last quarter, and how many were granted? Discover the latest information here.
Bayer CEO launches ‘full-scale effort’ to rejuvenate pharma pipeline, tables split-up but warns not never
Fierce Pharma
MARCH 5, 2024
Bill Anderson, nine months into Bayer’s CEO role, has laid out his priorities for the troubled German conglomerate in the next few years—and it doesn’t involve an immediate business split-up as man | Bill Anderson, nine months into Bayer’s CEO role, has laid out his priorities for the troubled German conglomerate in the next few years—and it doesn’t involve an immediate business split-up as many investors had hoped for.
A2 Bio’s cell therapy gains FDA orphan drug status for colorectal cancer
Pharmaceutical Technology
MARCH 5, 2024
A2 Bio has received the US FDA's orphan drug designation for its cell therapy, A2B530, to treat colorectal cancer patients.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Womb condition checks could reduce cancer risk in endometrial hyperplasia
Pharma Times
MARCH 5, 2024
Women with atypical endometrial hyperplasia have an increased risk of developing cancer
Nocion secures Series B funds to develop cough treatment
Pharmaceutical Technology
MARCH 5, 2024
Nocion has secured $62m in Series B financing round to advance its lead programme, Taplucanium, into later-stage development.
Surprise Enhertu rejection follows NICE process change
pharmaphorum
MARCH 5, 2024
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.
Vanda's jet-lag approval hopes for Hetlioz quashed with FDA hearing rejection
Fierce Pharma
MARCH 5, 2024
Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. | Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. Now, following a lawsuit and a protracted back-and-forth with the U.S. regulator, the FDA has crushed Vanda’s bid.
Can creative analytics solve your D2C paid search headache?
pharmaphorum
MARCH 5, 2024
Learn how creative analytics can help solve your Direct-to-Consumer paid search challenges. Discover how data-driven insights can optimise your performance with HCPs.
Sumitomo Pharma, suffering from sliding sales, lays off another 400 US staffers
Fierce Pharma
MARCH 5, 2024
Sumitomo Pharma’s hundeds of layoffs last summer weren't enough for the struggling company to stem the tide as its revenues decline and its
NICE backs frontline use of Jemperli in endometrial cancer
pharmaphorum
MARCH 5, 2024
GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 women across England, Wales and Northern Ireland.
GSK rewards CEO Walmsley with 51% pay hike after beating sales, profit goals
Fierce Pharma
MARCH 5, 2024
With the fortunes of GSK on the rise after much tumult early in the decade, the company has rewarded CEO Emma Walmsley with a significant pay boost. | With the fortunes of GSK on the rise after much tumult early in the decade, the company has rewarded CEO Emma Walmsley with a significant pay boost. Walmsley collected 12.7 million pounds ($16 million) in total pay last year, a 51% increase from her compensation in 2022.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Researchers develop brain-age prediction tool for diagnosis of neurological diseases
Pharma Times
MARCH 5, 2024
The non-invasive tool can also improve patient stratification and monitor disease progression
Novo Nordisk looks set to add another string to Ozempic bow
pharmaphorum
MARCH 5, 2024
Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease (CKD) in the FLOW trial.
Warren rebukes GSK for alleged 'money grab' after company pulled popular asthma med
Fierce Pharma
MARCH 5, 2024
In the aftermath of GSK’s decision to drop its brand-name asthma inhaler Flovent HFA in favor of an authorized generic, Sen. | After GSK’s decision to drop its brand-name asthma inhaler Flovent HFA in favor of an authorized generic, Sen. Elizabeth Warren (D-Mass.) has accused the British drugmaker of engaging in a “shameful money grab.” GSK, for its part, disagrees with the senator's assessment.
Pharma’s Medicare counteroffers are all in, says HHS
pharmaphorum
MARCH 5, 2024
HHS says all pharma companies affected by Medicare price negotiations have filed counteroffers, trumpeting the milestone as a sign the process is working
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Alamar Biosciences and ALZpath Announce Collaboration Centered on Furthering Alzheimer’s Disease Research
Pharmaceutical Commerce
MARCH 5, 2024
The pTau217 antibody helps pinpoint pathological changes related to the disease.
Words matter: The power of language in cancer discussions
pharmaphorum
MARCH 5, 2024
Explore the impact of language in cancer discussions and how it can influence patients' perceptions of therapy and oncology treatments. Understand the power of words in the context of cancer care.
Clerkenwell Health calling for volunteers with PTSD to trial new psychoactive drug
Outsourcing Pharma
MARCH 5, 2024
Clerkenwell Health, a company that delivers clinical trials for the treatment of complex mental health volunteers for trials into the use of psychoactive medications for treating PTSD, is in search of 40 ex-military volunteers.
Transitioning from traditional surgical methods to the innovative use of stem cells
pharmaphorum
MARCH 5, 2024
In today’s podcast, host Nicole Raleigh welcomes Dr Jeffrey Gross, founder of ReCELLebrate, neurological surgeon, and expert in the field of regenerative medicine, to discuss the recent appetite for the use of stem cells for longevity and explores the ‘health span’ notion that is being ever more frequently spoken of.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content